Advancing Hope: How Clinical Trials are Paving the Path to Better Treatments



CENTER FOR ADVANCED RESEARCH & EDUCATION


A Flourish Research Site

Angela Ritter, MD
Principal Investigator
Gainesville, Georgia

2025 DOUBLING DOWN on Dementia DEMENTIA SYMPOSI

2025 Alzheimer's Disease Facts

- An estimated 7.2 million Americans are living with Alzheimer's dementia.
- Non-Hispanic Black and Hispanic older adults are more likely than While adults to have Alzheimer's.
- In 2025, health and long-term care costs for people living with AD and other dementias are projected to reach $384 billion.
- More than 12 million Americans provide unpaid care for a family member/ friend with dementia, a contribution to the nation of over $413 billion.



2025
DOUBLING
DOWN
on Dementia
DEMENTIA SYMPOSI

Theories of Causation of Alzheimer's Dementia



- Amyloid plaque/Tau tangles
- Genetic/Lifestyle and Environmental factors
- Dysfunctional brain glucose metabolism (Type 3 DM)
- Lipid invasion across blood/brain barrier leading to neuroinflammation
- Autoimmune and autoinflammatory (called AD2)
- Gut microbiome imbalance

2025
Drug Development Pipeline



Diagnosis and Progression

Alzheimer's Dementia

Biomarkers for Alzheimer's

Imaging

- MRI (hippocampal volume measurement
- Beta amyloid PET scan
- Tau PET scan
- FDG-PET scan


Biofluids


- Blood based biomarkers: p-tau 217 and AB 42/40 ratio
- CSF measurement of amyloid and tau proteins

Genetic predisposition

Apo E (2,3 4 combo)

Stages of AD: Clinical and Pathological Changes





Center for Advanced Research & Education
a Flourish Research Site



Phases of Clinical Trials

Phase 1: tests the safety, side effects, best dose and timing of new treatments in humans; small group of subjects

Phase 2: mostly evaluates efficacy of treatment; more subjects than Phase 1; still evaluating safety

Phase 3: large trial of a treatment of drug that in Phase 1 and 2 has been shown to be effective with tolerable side effects: can test to see if new treatment is better than standard treatment; if successful after completion of the trial, may be approved by the FDA

Phase 4: large trial of an approved drug to get more information on safety, efficacy or test for new therapeutic use

Ongoing Clinical Trials at CARE/Flourish

Monoclonal Anti-Amyloid Antibody Drugs:

Removes amyloid from the brain

For Early to Mild AD:

- Eli Lilly (**Donanemab**) - IV * +/- pre-dosing with steroids
  * dosage modifications
- Roche (**Trontinemab**) - IV Faster and less ARIA?

For Pre-Clinical AD:

- Eli Lilly (**Remternetug**) - SC

Beta Amyloid Plaque and Tau Neurofibrillary Tangles



Ongoing Trials at CARE/Flourish

Inhibition of neurotoxic proteins in the brain (amyloid / beta, tau, alpha-synuclein and TDP43):

- Annovis (**Buntanetap**) – oral

Abnormal glucose metabolism in the brain:

- Novo Nordisk (**Semaglutide**) – oral

Muscarinic (M1/M4) receptor agonist in the brain:

- BMS (**KarXT + KarX-EC**) xanomeline with trospium - oral

Diagnostic Trials at CARE/Flourish

Biomarker testing with options to participate in current / future investigational trials:

- **Roche** (**p-Tau 217**) – ages 50-90
- **Eli Lilly** (**p-Tau 217**) – ages 65-80

What is it like to participate in a clinical trial?

Types of Clinical Trial Visits

- Informed Consent
- Screening Visit
- Baseline/ Randomization Visit
- Phone Call Visit
- End of Treatment Visit
- Follow up Visit





- Voluntary
- Protected Information
- No cost evaluation and treatments
- Treatment with drugs not currently available
- Compensation
- Being a part of “something bigger”


Keep
Moving
Forward

THANK YOU FOR JOINING US TODAY!

Your donation helps us build dementia preparedness in our communities with impactful programs like this symposium.

AND, PLEASE COMPLETE YOUR SURVEY !

ALZHEIMER'S ASSOCIATION

GEORGIA CHAPTER

Beyond Dementia Coalition

2025 DOUBLING DOWN on Dementia DEMENTIA SYMPOSI